Primary cardiac angiosarcomas although rare neoplasms remain the most common primary malignant neoplasms affecting the heart. We discuss the sequential positron-emission tomographycomputed tomography findings of a 50-year-old man who was diagnosed with the metastatic cardiac angiosarcoma at the outset and developed progressive disease despite sorafenib therapy.
A 50-year-old man diagnosed with primary cardiac angiosarcoma underwent . Angiosarcoma accounts for <1% among sarcomas and primary angiosarcoma of the heart and the great vessels accounts for only 3% of all the angiosarcomas [1] with an autopsy prevalence of 0.001%-0.28%. [2] Most of these tumors primarily arise in the right atrium, involving the lateral wall of the right atrium and mostly sparing the septum which results in delay in the initial diagnosis. [3] Frequent sites of extra-cardiac metastases include lung, liver, brain, bone, lymph nodes, adrenal glands, spleen, and intestine. [4] [5] [6] Our case had metastatic disease involving the lungs, adrenals, spleen, liver, and bones with all of them progressing on follow-up PET-CT scan. Utility of 18-F-FDG PET-CT in initial staging as a part of extra-cardiac metastatic work-up and response assessment to chemo or radiotherapy; although, scarce has been reported in the literature by Hod et al., Tan et al., Jain et al., and Dhull et al., respectively. [7] [8] [9] [10] Due to aggressive and rapidly progressive behavior of the primary and metastatic disease, we advocate extensive use of 18-F-FDG PET-CT as a "one-stop shop" for immaculate assessment of the disease burden during the initial staging and restaging purposes.
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